Vaxxinity

Vaxxinity

Our mission is to democratize health by pioneering the third biologic revolution

Founded 2019

United States 44 employees Grant Total: $9.25M Biotechnology, Pharmaceutical

Vaxxinity is a U.S.-based global biotechnology company that is pioneering a new class of medicines with the mission to democratize health. The company is headquartered in Dallas, TX and has operations in the United States, Latin America, Europe, and Asia. Vaxxinity's proprietary technology platform focuses on the innovation of synthetic peptide vaccines for both infectious diseases such as COVID-19, as well as chronic diseases including Alzheimer's, Parkinson’s, migraine, and hypercholesterolemia. The company's optimized pipeline aims to achieve a potentially historic global impact on human health. The key to Vaxxinity's platform lies in the proprietary library of UBITh peptides, which are immunosilent and can elicit highly specific antibodies when linked to custom-designed target antigens. The company was founded in 2019 and operates within the biotechnology and pharmaceutical industries. Their last investment of $9.25 million was a grant investment received on April 7, 2022 from the Coalition for Epidemic Preparedness Innovations. This significant investment underscores the recognition of Vaxxinity's potential to make a substantial impact on global healthcare.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	$9.25M	1	Coalition for Epidemic Preparedness Innovations	07 Apr 2022
Seed Round	Undisclosed	1	White Buffalo Capital	22 Apr 2020

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

$9.25M

Coalition for Epidemic Preparedness Innovations

07 Apr 2022

Seed Round

Undisclosed

White Buffalo Capital

22 Apr 2020

FAQ About Vaxxinity

Our mission is to democratize health by pioneering the third biologic revolution

Vaxxinity was founded in 2019.

Vaxxinity is headquartered in United States.

Vaxxinity operates in Biotechnology and Pharmaceutical. Its work centres on vaccines, chronic diseases, infectious diseases and synthetic peptide vaccines.

Vaxxinity has approximately 44 employees.

Vaxxinity has completed 2 funding rounds, raising a total of $9.25M. The latest funding stage is Grant.

Top alternatives and competitors to Vaxxinity include AFFiRiS AG, Affinivax Inc., Transgene, PRISM BioLab Co., Ltd., ILiAD Biotechnologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Vaxxinity and AFFiRiS AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Vaxxinity

Funding Rounds & Investors (2)

Vaxxinity Alternatives & Competitors

FAQ About Vaxxinity